EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
- Status
- RECRUITING
- Phase
- N/A
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy
- Status
- COMPLETED
- Phase
- N/A
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
- Status
- RECRUITING
- Phase
- NA
Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
- Status
- RECRUITING
- Phase
- PHASE2
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response
- Status
- WITHDRAWN
- Phase
- PHASE2
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy
- Status
- COMPLETED
- Phase
- N/A
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
- Status
- UNKNOWN
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
- Status
- COMPLETED
- Phase
- N/A
HER2-directed Biosimilar in Breast Cancer: Real World ePRO
- Status
- COMPLETED
- Phase
- N/A
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2